Facing the weight-loss battle? You're not alone. Many individuals turn to medication, hoping for a lasting solution. But a new study reveals a sobering truth: drugs alone might not be the answer for long-term weight control.
This international research, encompassing 37 studies and over 9,000 participants, examined the effectiveness of weight-loss medications, including GLP-1 receptor agonists, over time. The findings are quite revealing.
The study discovered that once patients stopped taking their medication, they not only regained weight, but their risk markers for diabetes and heart disease also reverted to their original levels within two years. For GLP-1 medications, data was available for up to 52 weeks after cessation.
And this is the part most people miss... The rate of weight regain after stopping these drugs is almost four times faster than after changes to diet and physical activity alone, regardless of how much weight was initially lost.
Researchers concluded that these medications, while effective for initial weight loss, may not be sufficient for long-term weight control. They emphasize the need for further research into cost-effective strategies for long-term weight management and reinforce the importance of primary prevention.
Dr. Trevor Steward, a senior research fellow at the University of Melbourne, confirms that this analysis aligns with what many doctors have observed: weight often returns after patients stop medication. He points out that many discontinue due to high costs, side effects, or the inconvenience of ongoing injections.
The key takeaway? Medications shouldn't be seen as a standalone cure. We need better evidence on how these medications work and what happens after stopping, including how to transition care and what lifestyle and psychological support helps maintain benefits.
But here's where it gets controversial... Access to and interest in weight-loss medications are rapidly increasing globally. In America, one in eight people have used injectable GLP-1 drugs. In Australia, hundreds of thousands are using these medications privately, spending up to $5,000 annually. The Australian government is considering adding GLP-1 drugs for weight loss to the Pharmaceutical Benefits Scheme.
Associate Professor Dominika Kwasnicka highlights the 'important policy implications' of this research, especially in this changing landscape. She notes the risk of short-term benefit followed by weight regain and loss of health gains without long-term planning. She supports embedding pharmacotherapy within comprehensive, long-term care models that include behavioral support and continuity of care, rather than viewing these medications as short-term solutions.
What are your thoughts? Do you believe weight-loss medications should be part of a comprehensive care plan, or do you have a different perspective? Share your opinions in the comments below!
